News & Updates
Filter by Specialty:

Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Liraglutide boosts lipid metabolism in T2DM, but comes with more side effects
02 Sep 2022
Compared with dapagliflozin, the glucagon-like peptide 1 liraglutide induces better lipid metabolism in patients with type 2 diabetes mellitus (T2DM), a recent study has found. However, this drug also comes with more adverse events than its sodium-glucose co-transporter 2 inhibitor comparator.